Proactive Investors - Run By Investors For Investors

AstraZeneca reports positive results from trial of pancreatic cancer treatment

Results from the trial of Lynparza showed “statistically significant and clinically meaningful improvement” in the time patients could live without their disease getting worse
Pancreatic
In 2018, there were 458,918 new cases of pancreatic cancer worldwide

AstraZeneca PLC (LON:AZN) said its Lynparza treatment nearly doubled the life-span of patients with metastatic pancreatic cancer in a phase III trial.

The trial tested Lynparza tablets as an initial maintenance treatment for metastatic pancreatic cancer patients, whose disease had not progressed after chemotherapy.

READ: AstraZeneca gets US regulatory green light for slow-release diabetes drug

Results showed “statistically significant and clinically meaningful improvement” in the time patients could live without their disease getting worse by an average of 7.4 months on Lynparza, compared to 3.8 months for those on placebo.

More than twice as many patients showed no disease progression both at one year and two years after starting to take Lynparza.  

José Baselga, executive vice president of oncology research and development, said: "These unprecedented results raise new hope for patients that have seen little progress over a long period of time.”

He said AstraZeneca is now working with regulatory authorities to bring Lynparza to patients “as quickly as possible”.

Pancreatic cancer has the worst survival rate of the most common cancers with less than 3% of patients surviving more than five years after diagnosis.

Early diagnosis of pancreatic cancer is difficult because there are usually no symptoms until it is too late.  About 80% of patients are diagnosed at the metastatic stage.

In 2018, there were 458,918 new cases of pancreatic cancer worldwide.

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
scientist in laboratory
May 24 2019
Here we take a closer look at healthcare investor NetScientific PLC (LON:NSCI)
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use